SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017 Oct 5, 2017
“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC) Aug 15, 2017
SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting Aug 14, 2017
SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Aug 3, 2017
New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains Jun 15, 2017
